Literature DB >> 10352062

Perception of chemotherapy side effects cancer versus noncancer patients.

C Lindley1, J S McCune, T E Thomason, D Lauder, A Sauls, S Adkins, W T Sawyer.   

Abstract

PURPOSE: This study was conducted to identify and compare perceptions regarding the disruption in quality of life caused by chemotherapy side effects in patients with cancer receiving chemotherapy and in noncancer, chemotherapy-naive patients. DESCRIPTION OF STUDY: One hundred forty-six patients with cancer and 224 patients without cancer completed two instruments to assess the perceived magnitude of 41 physical and psychosocial chemotherapy side effects. Instrument 1 used a 5-point Likert scale (1 = not at all; 2 = a little bit; 3 = somewhat; 4 = quite a bit; and 5 = very much) to summarize patient responses to the question, "How much did or would each of the following side effects of chemotherapy bother you?" Instrument 2 was a serial ranking questionnaire that asked patients to select the 10 most bothersome side effects to numerically rank the top five. An index of the relative magnitude of chemotherapy side effects was calculated for each instrument.
RESULTS: For patients with cancer, loss of hair 50%), changes in taste (46%), constantly being tired (42%), affects work duties (39%), changes in smell perception (35%) were most frequently perceived as bothering them "quite a bit" or "very much." Nausea and vomiting were ranked 11th and 22nd, respectively. With instrument 2, the five side effects perceived as most troublesome were, in decreasing order: nausea, loss of hair, constantly tired, vomiting, and changes in the way things taste. For noncancer patients, those factors potentially bothersome "quite a bit" or "very much" were: financial hardship (82%), hardship on family (78%), vomiting (73%), shortness of breath (70%), and ability to perform work duties (69%). Via instrument 2, the top five side effects, in decreasing order were: vomiting, hardship on family, loss of hair, financial hardship, nausea, having to move close to a treatment center. CLINICAL IMPLICATIONS: Noncancer, chemotherapy-naive patients perceived most chemotherapy-associated side effects as having greater impact on the quality of life than did cancer patients who had received chemotherapy. These findings can be used to direct patient education, education of the public, specific materials concerning cancer chemotherapy. The expertise of various members of the healthcare team can maximize the patient's comprehension of the adverse effects of the treatment options. The physician's knowledge of the overall treatment plan can assist in patient understanding; oncology pharmacists nurses are in a unique position to educate patients their families regarding potential chemotherapy side effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352062     DOI: 10.1046/j.1523-5394.1999.07205.x

Source DB:  PubMed          Journal:  Cancer Pract        ISSN: 1065-4704


  34 in total

1.  Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study.

Authors:  Xiaohui Zhang; Yidong Zhou; Feng Mao; Yan Lin; Jinghong Guan; Qiang Sun
Journal:  Med Oncol       Date:  2015-09-07       Impact factor: 3.064

Review 2.  Protection against chemotherapy-induced alopecia.

Authors:  Jie Wang; Ze Lu; Jessie L-S Au
Journal:  Pharm Res       Date:  2006-11       Impact factor: 4.200

3.  Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.

Authors:  Yuka Matsuda; Kenji Okita; Tomohisa Furuhata; Goro Kutomi; Kentaro Yamashita; Yasushi Sato; Rishu Takimoto; Koichi Hirata
Journal:  Support Care Cancer       Date:  2015-05-24       Impact factor: 3.603

4.  A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.

Authors:  Kenjiro Aogi; Hiroshi Sakai; Hirohisa Yoshizawa; Norikazu Masuda; Nobuyuki Katakami; Yasuhiro Yanagita; Kenichi Inoue; Masaru Kuranami; Mitsuhiro Mizutani; Noriyuki Masuda
Journal:  Support Care Cancer       Date:  2011-08-02       Impact factor: 3.603

5.  Self-reported taste and smell changes during cancer chemotherapy.

Authors:  Britt-Marie Bernhardson; Carol Tishelman; Lars E Rutqvist
Journal:  Support Care Cancer       Date:  2007-08-21       Impact factor: 3.603

6.  Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations.

Authors:  Floortje Mols; Corina J van den Hurk; Ad J J M Vingerhoets; Wim P M Breed
Journal:  Support Care Cancer       Date:  2008-06-17       Impact factor: 3.603

7.  Unanticipated toxicities from anticancer therapies: survivors' perspectives.

Authors:  Mona Gandhi; Karen Oishi; Beth Zubal; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2009-12-03       Impact factor: 3.603

Review 8.  Chemotherapy-induced nausea and vomiting: optimizing prevention and management.

Authors:  Kamakshi V Rao; Aimee Faso
Journal:  Am Health Drug Benefits       Date:  2012-07

9.  Self-care strategies to cope with taste changes after chemotherapy.

Authors:  Maureen Rehwaldt; Rita Wickham; Sandy Purl; Joseph Tariman; Carol Blendowski; Susan Shott; Mary Lappe
Journal:  Oncol Nurs Forum       Date:  2009-03       Impact factor: 2.172

10.  Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy.

Authors:  Edgar Petru; Johannes Andel; Lukas Angleitner-Boubenizek; Günther Steger; Marianne Bernhart; Kerstin Busch; Otto Gehmacher; Tamara Hernler; Uwe Kastner; Angelika Lanz-Veit; Ursula Pluschnigg; Jana Polachova; Michael Rohde; Lothar Schiller; Rene Schramböck; Wolfgang Stangl; Ralf Thödtmann; August Zabernigg
Journal:  Wien Med Wochenschr       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.